BACKGROUND: Currently there is no consensual agreement on the standard use of @entity1600 ( @entity1600 ) in staging of high-risk @entity1 . OBJECTIVE: The objective was to define the predictive value and role of @entity1600 combined with the different high-risk factors to determine which @entity1 could benefit from @entity1600 . METHOD: We conducted a review of the literature on @entity957 (SCC) and @entity1600 published in the year 2000 until May 2012. 173 @entity1 with @entity1544 and @entity1600 were found. Risk factors were listed along with lymph node status. Sensitivity, specificity and negative predictive value (NPV) were calculated for the cumulative results for each risk factor. RESULTS: Sensitivity for the total cohort was 79%, specificity was 100% and negative predictive value was 96%. The sensitivity, specificity and NPV were 78.26%, 100% and 95.14%, respectively, for @entity5 size >2  cm. Sensitivity, specificity and NPV for a @entity5 localized at a high-risk area were 72.63%, 100% and 96.74%, respectively. Specificity was 100% as was NPV for immunosuppression. CONCLUSION: @entity1600 has a high NPV and low false negative rate and carries a low risk of complications. @entity1600 may prove to enhance the survival or aid the prognosis of high-risk cSCC. Further, detailed investigations and longer follow-up times are needed to define the right group of @entity1 that could benefit from this procedure.

Utility of sentinel node biopsy in XXXX with high-risk @entity957 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity957 :: ('MESH:D002294', 'Disease') :: ['cutaneous squamous cell carcinoma'] @entity1600 :: ('MESH:D014388', 'Disease') :: ['SLNB', 'Sentinel Lymph Node Biopsy'] @entity1544 :: ('MESH:D018307', 'Disease') :: ['SCC tumors']
@entity1 :: (9606,Species) :: ['patients']
